A recent study by Future Market Insights (FMI) predicts significant growth in the global respiratory distress syndrome management market, which is expected to expand from US$ 115.4 billion in 2023 to US$ 177.7 billion by 2033, demonstrating a steady compound annual growth rate (CAGR) of 4.41%.
Respiratory Distress Syndrome (RDS) is a serious condition affecting newborn infants, particularly those born prematurely, characterized by breathing difficulties and an insufficient oxygen supply. The condition necessitates a comprehensive management strategy that includes medical, technological, and supportive care interventions.
Request A Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-16979
The market has seen notable growth driven by an increase in premature births, heightened awareness of neonatal health, and significant advancements in medical technologies. Key products and services boosting the market include ventilators, surfactant replacement therapies, non-invasive respiratory support devices, and specialized neonatal intensive care units (NICUs).
Technological innovations have played a pivotal role in the evolution of RDS management. Devices such as Continuous Positive Airway Pressure (CPAP) machines and High-Frequency Oscillatory Ventilation (HFOV) units have provided groundbreaking non-invasive support options for infants suffering from RDS. These technologies have led to improved patient outcomes, reduced complications, and enhanced comfort for the youngest patients.
Moreover, advancements in surfactant replacement therapies, including the development of synthetic surfactants and less invasive delivery methods, have significantly boosted survival rates and respiratory outcomes for premature infants.
The FMI report also highlights that industry sponsors are expected to lead the market with an anticipated share of approximately 54.7% in 2023. This reflects a robust interest and ongoing investment in developing and refining technologies and treatments that can improve the management of RDS.
As the market for Respiratory Distress Syndrome Management continues to evolve, the focus on innovation and effective treatment solutions remains paramount. The increasing prevalence of premature births globally and the rising demand for advanced medical interventions underscore the critical need for continued research and development in this field.
Key Takeaways from the Market Study:
- It is noted that the industry sponsors will be leading the market with an expected share of about 54.7% in the year 2023, within the global market.
- The global Respiratory Distress Syndrome Management Market grew at a CAGR of 4.24% from 2018 to 2022
- 4% of patients with respiratory distress syndrome required re-hospitalization.
- Out of 11.8 million admissions, it was also reported that 7.0% of hospitalizations involved an ICU stay, 3.8% of hospitalizations involved respiratory disease, and 10.3% of hospitalizations had a separation mode indicating the patient passed away in the hospital.
Methodology Details Just a Click Away: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16979
Competitive Landscape:
Some of the prominent players in the global market for RDS treatment are:
- JW Pharmaceutical
- Windtree Therapeutics, Inc.
- ONY Biotech Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc.
- Pfizer Inc.
- Gilead Sciences, Inc.
- Hoffmann-La Roche Ltd
- Fresenius Kabi AG
Some of the important developments of the key players in the market are:
- In May 2021, Medtronic announced the launch of the SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio.
- In July 2020, F. Hoffman-La Roche Ltd announced the launch of the SARS-CoV-2 rapid antibody test. The test was launched in partnership with SD Biosenseor, Inc. This has helped the company to increase its product portfolio.
Key Segments Profiled in the Respiratory Distress Syndrome Management Market Report:
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Drug Class:
- Vasoconstrictors
- Bronchodilators
- Steroids and Antibiotics
Route of administration:
- Oral
- Parenteral
- Nasal
End User:
- Hospital pharmacy
- Online pharmacy
- Retail pharmacy
Request Purchase Now: https://www.futuremarketinsights.com/checkout/16979
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
